New Approaches to Cocaine Abuse Medications (A)
Desipramine
+ Placebo
Behavior+4
+ Mental Disorders
+ Behavioral Symptoms
Treatment Study
Summary
Study start date: January 1, 1995
Actual date on which the first participant was enrolled.This is a randomized, 12-week, double-blind, 'placebo-controlled trial of outpatients meeting DSM-III-R criteria for cocaine dependence and major depression or dysthymia (by SCID interview). Participants were treated with desipramine, up to 300 mg per day, or matching placebo. All patients received weekly individual manual-guided relapse prevention therapy. Weekly outcome measures included the Clinical Global Impression Scale, self-reported cocaine use and craving, urine toxicology, and the Hamilton Depression Scale.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.111 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.From 18 to 60 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Inclusion: 1. Meets DSM-IV criteria for current cocaine dependence. 2. Used cocaine at least one day in the past month. 3. Currently meets DSM-IV criteria for Major Depression or Dysthymia. 4. Depressive disorder is either: 1. primary (antedates earliest lifetime substance abuse or 2. persistent during 6 months of abstinence in the past or 3. at least 3 months duration in the current episode 5. Age 18-60. 6. Able to give informed consent and comply with study procedures. Exclusion: 1. Meets DSM-IV criteria for past mania (i.e. bipolar disorder), schizophrenia or any psychotic disorder other than transient psychosis due to drug abuse. 2. History of seizures. 3. History of allergic reaction to desipramine or imipramine. 4. Chronic organic mental disorder. 5. Significant current suicidal risk. 6. Pregnancy, lactation or failure in sexually active female patients to use adequate contraceptive methods. 7. Unstable physical disorders which might make participation hazardous such as hypertension, hepatitis or diabetes. 8. Coronary vascular disease as indicated by history or suspected by abnormal ECG or history or cardiac symptoms. 9. Cardiac conduction system disease as indicated by QRS duration \>0.11. 10. Current use of other prescribed psychotropic medications within the last 2 weeks. 11. History of failure to respond to a previous adequate trial of desipramine or another tricyclic antidepressant. 12. Currently meets criteria for another substance dependence disorder (DSM-IV) other than nicotine, marijuana or alcohol.
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.2 intervention groups are designated in this study
50% chance of being blinded to the placebo group
Treatment Groups
Group I
ExperimentalGroup II
PlaceboStudy Objectives
Primary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
Research Foundation for Mental Hygiene
New York, United StatesOpen Research Foundation for Mental Hygiene in Google Maps